MedTrace Logo

Prognostic Relevance of Biological Subtype in Breast Cancer

NCT02063906 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2017-05-01

No results posted yet for this study

Summary

Recently, the investigators face "on the edges" for treatment decision to decide adjuvant systemic treatment, especially for patients who show discordance between stage and tumor biology. The aim of this study was to compare the prognostic relevance of the TNM staging system and intrinsic subtype in breast cancer patients who received curative surgery.

Conditions

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Young-Hyuck Im, Pf · Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2018-04-30
Completion
2019-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02063906 on ClinicalTrials.gov